



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 19 Apr 2022 (#15)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit [www.grants.nih.gov](http://www.grants.nih.gov) or [www.sun.ac.za/RDSfunding](http://www.sun.ac.za/RDSfunding) (current & archive).

**Confirm your intent to apply ASAP, but not later than 60 days before the submission date.**

Tygerberg Campus: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) • Stellenbosch Campus [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za)

## Important Notices

- **Urgent: Financial Conflict of Interest: All Principal Investigators (PIs) and Key Personnel (KP) of all current NIH grants, direct and subawards, must complete the NIH training and submit the certificate the Grants Management Office)** For all new applications, all PI's & KP must complete the certificate before the application can be submitted to NIH. This is in addition to the FCOI declarations that must be signed.
  - FMHS contact: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za)
  - Stellenbosch Campus contact [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za).

Link to the training: [https://grants.nih.gov/grants/policy/coi/tutorial2018/story\\_html5.html](https://grants.nih.gov/grants/policy/coi/tutorial2018/story_html5.html)

## Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

## Notices of Special Interest

- [NOT-DA-23-004](#) **High Priority Areas in Genetics, Epigenetics, and Developmental Neuroscience Branch in the Division of Neuroscience and Behavior.** The mission of the Division of Neuroscience and Behavior (DNB) is to discover, facilitate and promote outstanding basic animal and human research aimed at identifying the causes and consequences of drug addiction across the lifespan and to guide treatment strategies. The Genetics, Epigenetics, and Development (GED) Branch within DNB supports research on the genetics, epigenetics, and developmental mechanisms that underlie addiction and substance use disorders (SUD).

Research areas of general interest include but are not limited to:

- human and animal genetic studies of vulnerability to addiction,
- molecular genetics and genomic studies related to the response to addictive drugs,
- epigenetic mechanisms of substance use disorders and addiction,
- cell biology studies of addiction,
- development of neural pathways and brain structures that mediate SUDs and addiction and

- bioinformatic approaches to better model the genetics of SUDs, including data integration, methods development, epistasis analysis, and machine learning.

This notice applies to due dates on or after June 5, 2022 and subsequent receipt dates through September 8, 2025.

## Funding Opportunity Announcements (FOA)

### 1. Implementation Research to Reduce Noncommunicable Disease (NCD) Burden in Low- and Middle-Income Countries (LMICs) and Tribal Nations During Critical Life Stages and Key Transition Periods (R01 Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date **Hyperlink:** [PAR-22-132](#) **Type:** R01

**Application Due Date:** 27 July 01, 2022. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The National Institutes of Health (NIH) participating Institutes and Centers (ICs), in collaboration with the [Global Alliance for Chronic Diseases](#) (GACD), invite applications for implementation research focused on addressing risk factors for common noncommunicable diseases (NCDs) in [World Bank-defined low- and middle-income countries](#) (LMICs) and American Indian/Alaska Native (AI/AN) Tribal Nation populations in the United States. This Funding Opportunity Announcement (FOA) supports innovative approaches to identifying, understanding, developing, and implementing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, tools, policies, and guidelines. In addition, studies to advance dissemination and implementation research methods and measures into application are encouraged. Specifically, this FOA invites applications that propose interventions targeting critical life stages (e.g., infancy, childhood, adolescence, pregnancy, older adults) and key transitions between life stages to reduce health risk and/or enhance positive health and lifestyle behaviors. All applications must be within the scope of the mission of one of the Institutes/Centers listed above (see "Components of Participating Organizations"). Applications will be accepted from US and World Bank-defined LMIC institutions only.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Applicants requesting \$500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application

### 2. Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Cancer and Precancerous Lesions Associated with Lethal Phenotypes (R01 Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date **Hyperlink:** [PAR-22-131](#) **Type:** R01

**Application Due Date:** October 05, 2022 through to June 05, 2025. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) will support the development of state-of-the-art projects that integrate imaging, biomarkers, digital pathomics, glycomics, metabolomics, other omic information and/or meta data obtained from platforms including but not limited to lower resolution diagnostic acquisitions and systemic biomarker results to high resolution single-cell analytics / imaging applied to the characterization of heterogeneous cell populations within tumor for improving current approaches for: (1) the early detection of organ confined premetastatic aggressive cancer, and, (2) identifying precancerous lesions associated with the development of a subsequent lethal phenotype. This FOA specifically attempts to address and improve diagnostic uncertainty in clinical decisions by improving detection sensitivity and specificity of integrated multiparametric platforms. For example, N-dimensional co-registered, cross-correlated imaging data integrated with multiplexed biomarker results and/or digital pathomics, glycomics, or metabolomic imaging using analytic strategies such as artificial intelligence or virtual reality visualization techniques. The projects supported by this FOA will collectively participate in the existing Consortium for Imaging and Biomarkers (CIB) Research Program. The goals of the CIB are to: (1) improve diagnostic performance by developing methodology for the early identification of potentially lethal cancer versus non-lethal disease, (2) minimize/better manage overdiagnosis and (3) reduce false positives and false negatives. This FOA will utilize the NIH Research Project Grant (R01) mechanism and is suitable for projects where proof-of-principle of the individual proposed methodologies have already been established and supportive preliminary data are available.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

### 3. National Eye Institute (NEI) Cooperative Agreement for Early-Stage Clinical Trials with Greater than Minimal Risk (U01 Clinical Trial Required)

**Letter of Intent:** 30 days prior to the application due date **Hyperlink:** [PAR-22-149](#) **Type:** U01

**Application Due Date:** May 24, 2022 through to May 07, 2025. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The NEI uses U01 cooperative agreement awards to support investigator-initiated early-stage clinical trials that are greater than minimal risk and typically are Phase I or II trials. The risk level of the U01 trial requires appropriate performance oversight and safety monitoring. For purposes of this FOA, the proposed study must be intended to evaluate interventions aimed at screening, diagnosing, preventing, or treating vision disorders. Applicants are strongly advised to consult with NEI program staff prior to submitting an application with human subjects to determine the appropriate funding opportunity.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum period is five years. Applicants requesting \$500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application

#### 4. Research Opportunities in Established Cancer Epidemiology Cohort Studies (U01 Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-22-162](#)

**Type:** U01

**Application Due Date:** July 29, 2022 through to February 28, 2025. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) encourages grant applications to support research in *established* cancer epidemiology cohort studies, defined as studies that have achieved their initial planned recruitment goal. Applications must include hypothesis-based research using data from an established cohort study and are expected to include support for cohort maintenance, continued follow-up, and sharing of the existing resources in addition to addressing research questions across the cancer control continuum.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years. Applicants requesting \$500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 8 weeks before submitting the application

#### 5. Technologies and Assays for Therapeutic Genome Editing INDs (U01, Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-RM-22-014](#)

**Type:** U01

**Application Due Date:** 19 July 01, 2022. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:**

**Budget:** The NIH Common Fund intends to commit approximately \$2,000,000 per year for three years. Approximately four awards are anticipated, contingent upon availability of funds and receipt of a sufficient number of meritorious applications. Application budgets should not exceed \$300,000 direct costs per year in FY 2023-FY 2025 and need to reflect the actual needs of the proposed project. The maximum budget period is 3 years (FY 2023-2025).

Research Development and Support Division (RDSD),  
Faculty of Medicine and Health Sciences  
5<sup>th</sup> Floor, Teaching Block, Tygerberg Campus.  
Enquiries: *Christa*  
e: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) | t: +27 21 938 9838

Division for Research Development (DRD)  
Stellenbosch Campus  
2041 Krotoa Building, Ryneveld Street  
Enquiries: *Lizél*  
e: [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za) | t: +27 21 808 2105